查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1404004

全球多囊性卵巢症候群治疗市场-全球产业分析,规模,份额,成长,趋势,预测(2031)-按药物类别、按分销管道、按地区

Polycystic Ovary Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 306 Pages | 商品交期: 2-5个工作天内

价格
简介目录

预计到2024年底，多囊性卵巢症候群（PCOS）治疗的全球市场规模将达到42亿美元，到2031年预计将大幅扩大至61.1亿美元。多囊性卵巢症候群是一种影响女性的复杂内分泌疾病，其特征是卵巢囊肿、不孕症和内分泌波动。

多囊性卵巢症候群（PCOS）是一项重大的全球健康挑战，影响着全球数百万名女性。根据世界卫生组织 (WHO) 统计，全球有超过 1.16 亿女性 (3.4%) 患有 PCOS。光是在美国，PCOS 就影响了 6% 至 12% 的育龄女性，是女性不孕的主要原因。

多囊性卵巢症候群不限于特定年龄组，甚至在停经后女性中也可能持续存在，导致代谢变化和心血管疾病风险增加。早期诊断和治疗不仅对于缓解症状至关重要，而且对于预防长期影响也至关重要。

随着人们对多囊性卵巢症候群及其相关风险的认识不断提高，对诊断和治疗的需求也在增加。PCOS 意识协会 (PCOSAA) 等意识计画和倡议正在帮助提高诊断率。

为了应对不断增加的多囊性卵巢症候群诊断数量，製造商正在增加其提供的药物和营养补充剂的种类。创新的替代方案和改进的治疗方法预计将提高采用率。

FDA 核准的 PCOS 治疗方法数量有限，迫使个人使用适应不同目的的标籤外治疗方法。缺乏 FDA 批准的针对 PCOS 相关症状的治疗方法阻碍了市场的成长。

在欠发达经济体中，人们对多囊性卵巢症候群及其症状的认知仍然很低。再加上缺乏了解和对治疗的无忧无虑的态度，可能会阻碍市场的扩张。

该报告研究了全球多囊性卵巢症候群治疗市场，并提供了市场概况，包括按药物类别、分销管道、地区划分的趋势以及进入市场的公司的竞争趋势。

目录

第一章执行摘要

第二章市场概况

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • COVID-19 影响分析
  • 乌克兰与俄罗斯衝突的影响
  • 经济概况
  • PESTLE分析

第三章 2018-2031 年全球多囊性卵巢症候群 (PCOS) 治疗市场展望

  • 全球多囊性卵巢症候群 (PCOS) 治疗市场展望，按药物类别、价值（十亿美元），2018-2031 年
  • 全球多囊性卵巢症候群 (PCOS) 治疗市场展望（按分销管道）、价值（十亿美元），2018-2031 年
  • 全球多囊性卵巢症候群 (PCOS) 治疗市场展望（按地区、价值（十亿美元）），2018-2031 年

第四章 2018-2031 年北美多囊性卵巢症候群 (PCOS) 治疗市场展望

第五章 2018-2031 年欧洲多囊性卵巢症候群 (PCOS) 治疗市场展望

第六章 2018-2031 年亚太地区多囊性卵巢症候群 (PCOS) 治疗市场展望

第 7 章 2018-2031 年拉丁美洲多囊性卵巢症候群 (PCOS) 治疗市场展望

第 8 章 2018-2031 年中东和非洲多囊性卵巢症候群 (PCOS) 治疗市场展望

第9章 竞争格局

  • 按药物类别和分销管道划分的热图
  • 2023 年公司市场份额分析
  • 竞争力仪表板
  • 公司简介
    • Novartis AG
    • Sanofi
    • Teva Pharmaceutical Industries Limited
    • Merck & Co., Inc. (Merck group)
    • AstraZeneca plc.
    • Bayer AG
    • Abbott
    • Pfizer, Inc
    • Bristol-Myer Squibb Company
    • Ferring Pharmaceuticals, Inc.
    • Johnson and Johnson
    • Mylan N.V.
    • Allergan plc.
    • GlaxoSmithKline
    • Lupin Pharmaceuticals
    • AbbVie
    • Takeda
    • BIOCAD Global
    • Blairex Laboratories Inc

第10章附录

简介目录

The global polycystic ovary syndrome (PCOS) treatment market, valued at US$ 4.2 billion at the end of 2024, is forecasted to witness substantial growth, with an estimated valuation of US$ 6.11 billion by 2031. PCOS, a complex endocrine condition affecting women, is characterized by ovarian cysts, subfertility, and endocrine variations.

PCOS: A Global Health Concern

Polycystic ovarian syndrome (PCOS) poses a significant global health challenge, affecting millions of women worldwide. According to the World Health Organization (WHO), over 116 million women (3.4%) globally suffer from PCOS. In the United States alone, PCOS accounts for 6% to 12% of cases among women of reproductive age, making it a leading cause of female infertility.

PCOS is not limited to a specific age group, as it can persist even in postmenopausal women, leading to metabolic changes and an increased risk of cardiovascular disease. Early diagnosis and treatment are crucial not only to alleviate symptoms but also to prevent long-term consequences.

Opportunities for PCOS Drug Manufacturers:

Changing Lifestyles and Rising Awareness: With a growing awareness of PCOS and its associated risks, there is an increasing demand for diagnosis and treatment. Awareness programs and initiatives, such as PCOS Awareness Association (PCOSAA), are contributing to higher diagnosis rates.

Innovative Treatment Modalities: Manufacturers are offering an expanded range of drug formulations and dietary products to cater to the rising number of PCOS diagnoses. Innovative alternatives and improved treatment options are expected to boost adoption rates.

Challenges Faced by Market Players:

Unavailability of FDA-Approved Drugs: Limited FDA-approved drugs for PCOS treatment force individuals to use off-label drugs intended for different purposes. The absence of FDA-approved treatments for PCOS-related symptoms hinders market growth.

Lack of Awareness in Underdeveloped Economies: In underdeveloped economies, awareness regarding PCOS and its symptoms remains significantly low. This, coupled with a lack of understanding and a carefree attitude towards treatment, can hinder market expansion.

Country-Wise Insights:

Lucrative U.S. Market: The United States experiences rising healthcare costs and an increasing prevalence of PCOS-related disorders. Improved healthcare infrastructure, rising disposable income, and government-led awareness initiatives contribute to market growth.

Growing Indian Market: India has witnessed a surge in PCOS diagnoses, with approximately 22.5% of women affected. Increased awareness, changing lifestyles, and dietary habits are driving the demand for PCOS treatment in the country.

Competitive Landscape:

Leading manufacturers and pharmaceutical companies are focusing on developing innovative products to strengthen their global product pipelines. Collaborations and consolidation activities with other firms are being pursued to expedite research, development, and distribution.

Key Companies Profiled:

  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Limited
  • Merck & Co., Inc. (Merck group)
  • AstraZeneca plc.
  • Bayer AG
  • Abbott
  • Pfizer, Inc
  • Bristol-Myer Squibb Company
  • Ferring Pharmaceuticals, Inc.
  • Johnson and Johnson
  • Mylan N.V.
  • Allergan plc.
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • AbbVie
  • Takeda
  • BIOCAD Global
  • Blairex Laboratories Inc
  • Agile Therapeutics

Key Segments of PCOS Treatment Industry Research

By Drug Class:

  • Oral Contraceptives
  • Insulin Sensitizing Agents
  • Antidepressants
  • Ornithine Decarboxylase Inhibitors
  • Aromatase Inhibitors & SERMs
  • Diuretics

By Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores/OTC
  • e-Commerce
  • Clinics

By Region:

  • North America
  • Latin America
  • Europe Polycystic
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Oral Contraceptives
      • 3.1.1.2. Insulin Sensitizing Agents
      • 3.1.1.3. Antidepressants
      • 3.1.1.4. Ornithine Decarboxylase Inhibitors
      • 3.1.1.5. Aromatase Inhibitors & SERMs
      • 3.1.1.6. Diuretics
  • 3.2. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Drug Stores/OTC
      • 3.2.1.3. e-Commerce
      • 3.2.1.4. Clinics
  • 3.3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Oral Contraceptives
      • 4.1.1.2. Insulin Sensitizing Agents
      • 4.1.1.3. Antidepressants
      • 4.1.1.4. Ornithine Decarboxylase Inhibitors
      • 4.1.1.5. Aromatase Inhibitors & SERMs
      • 4.1.1.6. Diuretics
  • 4.2. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Drug Stores/OTC
      • 4.2.1.3. e-Commerce
      • 4.2.1.4. Clinics
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Oral Contraceptives
      • 5.1.1.2. Insulin Sensitizing Agents
      • 5.1.1.3. Antidepressants
      • 5.1.1.4. Ornithine Decarboxylase Inhibitors
      • 5.1.1.5. Aromatase Inhibitors & SERMs
      • 5.1.1.6. Diuretics
  • 5.2. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Drug Stores/OTC
      • 5.2.1.3. e-Commerce
      • 5.2.1.4. Clinics
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Oral Contraceptives
      • 6.1.1.2. Insulin Sensitizing Agents
      • 6.1.1.3. Antidepressants
      • 6.1.1.4. Ornithine Decarboxylase Inhibitors
      • 6.1.1.5. Aromatase Inhibitors & SERMs
      • 6.1.1.6. Diuretics
  • 6.2. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Drug Stores/OTC
      • 6.2.1.3. e-Commerce
      • 6.2.1.4. Clinics
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Oral Contraceptives
      • 7.1.1.2. Insulin Sensitizing Agents
      • 7.1.1.3. Antidepressants
      • 7.1.1.4. Ornithine Decarboxylase Inhibitors
      • 7.1.1.5. Aromatase Inhibitors & SERMs
      • 7.1.1.6. Diuretics
  • 7.2. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Drug Stores/OTC
      • 7.2.1.3. e-Commerce
      • 7.2.1.4. Clinics
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Oral Contraceptives
      • 8.1.1.2. Insulin Sensitizing Agents
      • 8.1.1.3. Antidepressants
      • 8.1.1.4. Ornithine Decarboxylase Inhibitors
      • 8.1.1.5. Aromatase Inhibitors & SERMs
      • 8.1.1.6. Diuretics
  • 8.2. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Drug Stores/OTC
      • 8.2.1.3. e-Commerce
      • 8.2.1.4. Clinics
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Drug Class vs by Distribution Channel Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novartis AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Therapy Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Sanofi
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Therapy Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Teva Pharmaceutical Industries Limited
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Therapy Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Merck & Co., Inc. (Merck group)
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Therapy Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. AstraZeneca plc.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Therapy Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Bayer AG
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Therapy Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Abbott
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Therapy Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Pfizer, Inc
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Therapy Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Bristol-Myer Squibb Company
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Therapy Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Ferring Pharmaceuticals, Inc.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Therapy Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Johnson and Johnson
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Therapy Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Mylan N.V.
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Therapy Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Allergan plc.
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Therapy Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development
    • 9.4.14. GlaxoSmithKline
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Therapy Portfolio
      • 9.4.14.3. Financial Overview
      • 9.4.14.4. Business Strategies and Development
    • 9.4.15. Lupin Pharmaceuticals
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Therapy Portfolio
      • 9.4.15.3. Financial Overview
      • 9.4.15.4. Business Strategies and Development
    • 9.4.16. AbbVie
      • 9.4.16.1. Company Overview
      • 9.4.16.2. Therapy Portfolio
      • 9.4.16.3. Financial Overview
      • 9.4.16.4. Business Strategies and Development
    • 9.4.17. Takeda
      • 9.4.17.1. Company Overview
      • 9.4.17.2. Therapy Portfolio
      • 9.4.17.3. Financial Overview
      • 9.4.17.4. Business Strategies and Development
    • 9.4.18. BIOCAD Global
      • 9.4.18.1. Company Overview
      • 9.4.18.2. Therapy Portfolio
      • 9.4.18.3. Financial Overview
      • 9.4.18.4. Business Strategies and Development
    • 9.4.19. Blairex Laboratories Inc
      • 9.4.19.1. Company Overview
      • 9.4.19.2. Therapy Portfolio
      • 9.4.19.3. Financial Overview
      • 9.4.19.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations